1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Joy Hu
Joy Hu
Articles (294) 

Weekly CEO Buys Highlight

Details the CEO buys of the following companies: New Fortress Energy LLC, EQT Corp, OPKO Health and Esperion Therapeutics

April 07, 2019 | About:

According to GuruFocus Insider Data, these are the largest CEO buys during the past week.

New Fortress Energy LLC CEO bought 186,099 shares

New Fortress Energy LLC (NASDAQ:NFE) CEO and 10% Owner Wesley R. Edens bought 186,099 shares on March 29 at a price of $11.29. The price of the stock has increased by 12.05% since.

The energy infrastructure company delivers energy solutions to customers so they can use natural gas for power. The company has a market cap of $2.12 billion. Its shares were trading at $12.65 on April 5.

On Jan. 30, the company announced the pricing of its initial public offering of 20 million Class A shares at $14 per share.

Edens also bought 592,100 shares on March 28 at a price of $9.84.

Director David J. Grain bought 4,500 shares on April 1 at a price of $11.29. The price of the stock has increased by 12.05% since.

Director Matthew Wilkinson bought 12,500 shares on March 28 at a price of $9.97. The price of the stock has increased by 26.88% since.

Director and 10% Owner Randal A. Nardone bought 580,000 shares on March 28 at a price of $9.85. The price of the stock has increased by 28.43% since.

EQT Corp. CEO bought 12,660 shares

EQT Corp. (NYSE:EQT) President and CEO Robert Joseph Mcnally bought 12,660 shares on March 29 at a price of $20.80. The price of the stock has increased by 3.89% since.

EQT is a natural gas exploration and production company. It produces natural gas from proved natural gas, natural gas liquid and crude oil reserves; and also provides gathering, transmission and storage services for the company's produced gas. The company has a market cap of $5.51 billion. Its shares traded at $21.61 as of April 5.

Net loss for the fourth quarter of 2018 was $598 million compared to $1.28 billion for the prior-year quarter.

Senior Vice President and Chief Financial Officer Jimmi Sue Smith bought 6,000 shares on March 14 at a price of $19.79. The price of the stock has increased by 9.2% since.

Director Daniel J. Rice IV bought 1,025 shares on April 1 at a price of $20.74. The price of the stock has increased by 4.19% since.

Director Gerald F. MacCleary bought 1,085 shares on April 1 at a price of $20.74. The price of the stock has increased by 4.19% since.

Director A. Bray Cary Jr. bought 1,205 shares on April 1 at a price of $20.74. The price of the stock has increased by 4.19% since.

Executive Vice President of Production Erin R. Centofanti bought 7,765 shares on March 29 at a price of $20.83. The price of the stock has increased by 3.74% since.

OPKO Health CEO bought 80,000 shares

OPKO Health Inc. (NASDAQ:OPK) CEO, Chairman, and 10% Owner Phillip Frost bought 80,000 shares during the past week at the average price of $2.54.

The diversified health care company seeks to establish industry-leading positions in large, rapidly growing markets. The company has a market cap of $1.61 billion. Its shares traded at $2.61 as of April 5.

Net loss for the first quarter of 2018 was $43.1 million compared to a net loss of $34.5 million for the comparable period of 2017.

Frost bought 40,000 shares on March 18 at a price of $2.47; 100,000 shares on March 27 at a price of $2.49; 20,000 shares on April 1 at a price of $2.58; 40,000 shares on April 2 at a price of $2.53; and 20,000 shares on April 4 at a price of $2.53. The price of the stock has increased by 3.16% since.

Esperion Therapeutics CEO bought 5,000 shares

Esperion Therapeutics Inc. (NASDAQ:ESPR) President and CEO Timothy M. Mayleben bought 5,000 shares on March 29 at a price of $40.00. The price of the stock has increased by 7.4% since.

Esperion Therapeutics Inc is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C, lowering therapies for the treatment of patients with elevated LDL-C. The company has a market cap of $1.15 billion. Its shares traded at $42.96 as of April 5.

Net loss for the fourth quarter of 2018 was $60.04 million compared to $37.89 million for the prior-year period.

Mayleben bought 5,000 shares on March 14 at a price of $48.73 and 5,000 shares on March 20 at a price of $43.48.

Chief Financial Officer Richard Bartram sold 8,000 shares on March 3 at a price of $42.88. The price of the stock has increased by 0.19% since.

10% Owner Biotech Target N. V. bought 50,000 shares on March 14 at a price of $49.89. The price of the stock has decreased by 13.89% since.

Director Nicole Vitullo sold 15,329 shares on March 19 at a price of $44.73. The price of the stock has decreased by 3.96% since.

Director Roger S. Newton sold 25,000 shares on March 12 at a price of $50.06. The price of the stock has decreased by 14.18% since.

For the complete list of stocks that bought by their company CEOs, go to: CEO Buys.

Disclosure: I do not own stock in any of the companies mentioned in the article.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Joy Hu


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)